Resonance Specialties Ltd Approves Q1 FY27 Unaudited Results & Facility Purchase
Resonance Specialties Ltd announced that its Board of Directors has approved the unaudited financial results for the first quarter ended June 30, 2026. Additionally, the board approved the purchase of a manufacturing facility, including land, buildings, plant & machinery, and licenses, located in Mandideep, Madhya Pradesh, from Kaygee Laboratories Private Limited, a related party. The acquisition will be on a slump sale basis for a consideration of ₹29.98 crores, subject to shareholder approval. The transaction is considered a related party transaction and has been conducted at arm's length, supported by an independent valuation certificate. The rationale for the acquisition includes securing uninterrupted production, enhancing operational control and efficiency, and eliminating outsourcing costs for essential chemical intermediates and APIs.
Key Highlights
- Board approved unaudited financial results for Q1 FY27.
- Approved purchase of manufacturing facility for ₹29.98 crores.
- Acquisition is from Kaygee Laboratories Private Limited, a related party.
- Transaction is on a slump sale basis, subject to shareholder approval.
- Rationale includes securing production and enhancing operational efficiency.
Price Impact
More from RESONANCE